# Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

> **NCT00004248** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 24 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **DRUG:** doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00004248
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2000-06
- **Final completion:** 2001-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004248, "Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*